Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. breast model for milk
Show results for
Products

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Breast Model For Milk Articles & Analysis

13 news found

Annual General Meeting of Infant Bacterial Therapeutics

Annual General Meeting of Infant Bacterial Therapeutics

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet; that no dividend is made; discharge from liability granted to Board members and the managing director, that the Board shall consist of ...

ByInfant Bacterial Therapeutics AB


Fecal biomarkers - diagnostic possibilities in the context of inflammatory bowel disease

Fecal biomarkers - diagnostic possibilities in the context of inflammatory bowel disease

Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. The chronic progression of IBD is characterized by periods of symptomatic relapses and symptom-free phases. During relapses, acute inflammation occurs in the bowel of IBD patients, leading to typical symptoms ...

ByImmundiagnostik AG


FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis (EoE), a chronic and progressive type 2 inflammatory ...

ByRegeneron Pharmaceuticals Inc.


Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union. Dupixent is now also approved in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised ...

ByRegeneron Pharmaceuticals Inc.


Infant Bacterial Therapeutics publishes Annual Report for 2021

Infant Bacterial Therapeutics publishes Annual Report for 2021

Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media – Financial Reports” and is available in printed form for those that have requested. A copy can be requested by contacting IBT’s office via info@ibtherapeutics.com. About Infant ...

ByInfant Bacterial Therapeutics AB


UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients

UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced the first published report of real-world experience utilizing the antegrade approach for Jelmyto® (mitomycin) for pyelocalyceal solution administration in the Journal of Urology online on February 7, 2022. This report provides a stepwise ...

ByUroGen Pharma, Inc.


Recruitment of the smallest infants in the Connection study paused

Recruitment of the smallest infants in the Connection study paused

IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per ...

ByInfant Bacterial Therapeutics AB


Infant Bacterial Therapeutics receives additional patent protection in China

Infant Bacterial Therapeutics receives additional patent protection in China

Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid bacteria, which protects formulations of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of ...

ByInfant Bacterial Therapeutics AB


New study:  Nine out of ten U.S. infants experience gut microbiome deficiency

New study: Nine out of ten U.S. infants experience gut microbiome deficiency

A new peer-reviewed study reveals that the vast majority of U.S. infants may be suffering from a substantial deficiency in an important bacterium key to breast milk utilization and immune system development, as well as protection against gut pathogens linked to common newborn conditions such as colic and diaper rash. According to the study published today in Scientific Reports, approximately ...

ByEvolve BioSystems, Inc.


Soap antimicrobial may damage liver and raise cancer risk, mouse study shows

Long-term exposure to triclosan, an antimicrobial agent commonly found in a broad array of soaps, shampoos, toothpastes and other consumer products, may have potentially serious health consequences, reports a research team including a UC Davis scientist. Data from a new study shows that triclosan causes liver fibrosis and cancer in laboratory mice through molecular mechanisms that are also ...

ByNational Institute of Environmental Health Sciences (NIEHS)


CIHs Qualified to Assist with Ebola Outbreak

CIHs Qualified to Assist with Ebola Outbreak

This year, the largest Ebola epidemic in history occurred in multiple countries across West Africa. In September, a person who traveled from Africa to the United States was diagnosed with the condition in Texas. The virus then spread to several healthcare workers who provided the patient with medical care. Others who offered medical care in West Africa have also become infected and have been ...

ByCochrane & Associates, LLC


Possible Link between BPA and Higher Obesity Rates

Possible Link between BPA and Higher Obesity Rates

Last month, Fox News published information about a recent study linking exposure to BPA and higher risk of obesity in girls between the ages of 9 and 12. Bisphenol A has long been associated with other potential health risks, but the new study of over 1,300 children found that females with higher levels of BPA in their urine had a greater risk of being overweight. Interestingly, the same ...

ByEMSL Analytical, Inc.


CSIRO and Clover to develop new, healthy ingredients for infant formulas

CSIRO and ingredients manufacturer, Clover Corporation Limited, are developing the next generation of nutritional ingredients for infant formulas. CSIRO and leading Australian ingredients manufacturer, Clover Corporation Limited, have agreed to work together on the development of the next generation of nutritional ingredients for infant formulas. “While natural breast milk is the gold ...

ByCSIRO, the Commonwealth Scientific and Industrial Research Organisation

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT